IRADIMED reports record Q1 revenue of $17.6M, up 13.7% YoY; EPS $0.32 GAAP, $0.36 non-GAAP

IRADIMED CORP

2024-Q1 EPS reported $0.32 revenue$17,598,119

Q1 2024 record revenue $17.6M, +13.7% YoY; operating income $4.7M, +18.5%.
GAAP diluted EPS $0.32, non-GAAP $0.36; net income $4.1M, +21.4%.
Declared regular quarterly dividend of $0.15/share payable May 30, 2024 to holders of record May 20.
Q2 2024 guidance: revenue $17.6-17.8M, GAAP EPS $0.33-0.36, non-GAAP $0.36-0.39.
FY 2024 guidance reiterated: revenue $72-74M, GAAP EPS $1.37-1.47, non-GAAP $1.52-1.62.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IRADIMED CORP reported the three months ended March 31, 2024 results: revenue $17.6 million, net income $4.1 million, EPS $0.32 per diluted share. Guidance reaffirmed.

Period: the three months ended March 31, 2024
Revenue: $17.6 million
Net income: $4.1 million
EPS: $0.32 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

IRADIMED CORPORATION Announces First Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share ● Reports record revenue of $17.6 million for the first quarter of 2024. ● Reports GAAP diluted EPS of $0.32 and non-GAAP diluted EPS of $0.36 for the first quarter of 2024. ● Reports first quarter of 2024 operating

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

IRADIMED CORP filing history →

Source: SEC EDGAR

accession 0001558370-24-006460

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.